ATE426813T1 - Verfahren zur dosierung von ngf zur in vitro diagnose von brustkrebs und therapeutische verwendung - Google Patents

Verfahren zur dosierung von ngf zur in vitro diagnose von brustkrebs und therapeutische verwendung

Info

Publication number
ATE426813T1
ATE426813T1 AT03778473T AT03778473T ATE426813T1 AT E426813 T1 ATE426813 T1 AT E426813T1 AT 03778473 T AT03778473 T AT 03778473T AT 03778473 T AT03778473 T AT 03778473T AT E426813 T1 ATE426813 T1 AT E426813T1
Authority
AT
Austria
Prior art keywords
ngf
breast cancer
vitro diagnosis
dosing
therapeutic use
Prior art date
Application number
AT03778473T
Other languages
English (en)
Inventor
Eric Adriaenssens
Genevieve Choquet-Kastylevsky
Laurent Dolle
Belkoura El-Yazidi
Hubert Hondermarck
Original Assignee
Biomerieux Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux Sa filed Critical Biomerieux Sa
Application granted granted Critical
Publication of ATE426813T1 publication Critical patent/ATE426813T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
AT03778473T 2002-10-28 2003-10-28 Verfahren zur dosierung von ngf zur in vitro diagnose von brustkrebs und therapeutische verwendung ATE426813T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0213428A FR2846426B1 (fr) 2002-10-28 2002-10-28 Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie

Publications (1)

Publication Number Publication Date
ATE426813T1 true ATE426813T1 (de) 2009-04-15

Family

ID=32088308

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03778473T ATE426813T1 (de) 2002-10-28 2003-10-28 Verfahren zur dosierung von ngf zur in vitro diagnose von brustkrebs und therapeutische verwendung

Country Status (10)

Country Link
US (1) US7618790B2 (de)
EP (2) EP2085783A1 (de)
JP (1) JP4619125B2 (de)
AT (1) ATE426813T1 (de)
AU (1) AU2003285472B2 (de)
BR (1) BRPI0315735B8 (de)
DE (1) DE60326871D1 (de)
ES (1) ES2324818T3 (de)
FR (1) FR2846426B1 (de)
WO (1) WO2004040312A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4587281B2 (ja) * 2004-06-21 2010-11-24 則男 長尾 癌転移抑制能測定する方法およびその測定器
FR2896881B1 (fr) * 2006-01-31 2008-04-18 Biomerieux Sa Procede de dosage du prongf pour le diagnostic in vitro du cancer du sein et utilisation du prongf en therapie
EP2294406B1 (de) * 2008-06-05 2020-07-22 The Administrators Of The Tulane Educational Fund Vorrichtung und verfahren zur überwachung der polymerfunktionsentwicklung während der synthese
US8900588B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
JP7467866B2 (ja) * 2019-10-02 2024-04-16 住友ゴム工業株式会社 親水性基材及び親水性基材作製方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607507B1 (fr) 1986-12-02 1990-04-13 Centre Nat Rech Scient Nouveaux derives a-d-oligonucleotides, leur preparation et leur emploi
CA2143945A1 (en) * 1992-09-11 1994-03-31 Daniel Djakiew A method for the detection and treatment of prostate disease
FR2710075B1 (fr) 1993-09-15 1995-10-27 Bio Merieux Réactif et procédé pour la détection d'une séquence nucléotidique avec amplification de signal.
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
JP2000508171A (ja) * 1996-04-05 2000-07-04 ザ・ジョンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン 希少細胞の富化方法
US20030104364A1 (en) * 1997-06-25 2003-06-05 Patricia A. Billing-Medel Reagents and methods useful for detecting diseases of the breast
US6008003A (en) * 1997-10-28 1999-12-28 Promega Corporation Non-invasive diagnostic method for interstitial cystitis and bladder cancer
FR2781802B1 (fr) 1998-07-31 2001-05-11 Bio Merieux Derives satures ou insatures de l'abietane, conjugues derives et utilisations dans une composition diagnostique, un reactif et un dispositif
EP1259604A1 (de) * 2000-02-25 2002-11-27 Oxford GlycoSciences (UK) Limited Bcmp 84, ein brustkrebs-assoziiertes protein
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
ATE331958T1 (de) 2002-03-13 2006-07-15 Biomerieux Sa Verfahren zum nachweis und zur quantifizierung von -aus soliden tumoren abstammenden- zirkulierenden tumorzellen

Also Published As

Publication number Publication date
ES2324818T3 (es) 2009-08-17
WO2004040312A2 (fr) 2004-05-13
BRPI0315735B8 (pt) 2021-05-25
BRPI0315735A8 (pt) 2018-09-18
EP1556699A2 (de) 2005-07-27
EP1556699B1 (de) 2009-03-25
EP2085783A1 (de) 2009-08-05
WO2004040312A3 (fr) 2004-06-17
JP4619125B2 (ja) 2011-01-26
US7618790B2 (en) 2009-11-17
AU2003285472B2 (en) 2009-10-08
US20060051818A1 (en) 2006-03-09
DE60326871D1 (de) 2009-05-07
FR2846426B1 (fr) 2004-12-10
BR0315735A (pt) 2005-09-06
FR2846426A1 (fr) 2004-04-30
BRPI0315735B1 (pt) 2018-10-30
AU2003285472A1 (en) 2004-05-25
JP2006504101A (ja) 2006-02-02

Similar Documents

Publication Publication Date Title
Lemma et al. MDA-MB-231 breast cancer cells fuel osteoclast metabolism and activity: A new rationale for the pathogenesis of osteolytic bone metastases
EP1640458A4 (de) Verfahren zur auswahl von für den wt1-impfstoff geeigneten patienten
DE60326871D1 (de) Verfahren zur dosierung von ngf zur in vitro diagnose von brustkrebs und therapeutische verwendung
DE60107815D1 (de) Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
ATE529535T1 (de) Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
CY1111612T1 (el) Μεθοδος για προβλεψη της αποκρισης σε μια θεραπευτικη αγωγη με εναν αναστολεαδιmερισmου του her
RU2013145524A (ru) Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона
EP2627321A1 (de) Behandlung von krebs/hemmung von metastasen
CY1119653T1 (el) Μεθοδος για ταυτοποιηση της ευαισθησιας ενος ασθενους σε θεραπεια αναστολης της τελομερασης
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
Lv et al. Blocking the Na+/H+ exchanger 1 with cariporide (HOE642) reduces the hypoxia-induced invasion of human tongue squamous cell carcinoma
NO994932L (no) Blandinger og fremgangsmåter for behandling og diagnose av brystkreft
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
Park et al. Hypoglycemia-induced VEGF expression is mediated by intracellular Ca2+ and protein kinase C signaling pathway in HepG2 human hepatoblastoma cells.
Reeves et al. Rejuvenating aged osteoprogenitors for bone repair
Estrada et al. Effects of TNF-α on the production of vasoactive substances by cerebral endothelial and smooth muscle cells in culture
RU2007141930A (ru) Способ in vitro идентификации соединений для лечения рака
DE602005022693D1 (de) Krebsdiagnose und behandlung unter verwendung eines anti-robo1-antikörpers
Jacob et al. Quality control for the validation of extracorporeal photopheresis process using the Vilbert–Lourmat UV-A irradiation’s system
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav
Satrawaha et al. Pressure induces interleukin-6 expression via the P2Y6 receptor in human dental pulp cells
WO2009051238A1 (ja) ヒト白血病幹細胞および白血病非幹細胞が増幅されたマウスおよびその製造方法
EP1602669A4 (de) Antikörper gegen tumorspezifisches antigen als target
Barron et al. Cnsc-01. gabaergic neuron-to-glioma synapses in diffuse midline gliomas
Pavelio et al. Antimetabolic activity of L-ascorbic acid in human and animal tumors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties